Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karen Kutikoff

Internal Medicine Loxahatchee, FL Medical Doctor

NPI 1710997994 CMS profile 123755

12957 Palms West Drive, Suite 201, Loxahatchee, FL 33470

Open in the dashboard

General payments

$7,089

393 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Kutikoff of Loxahatchee, FL is reported in the CMS Open Payments database as having received $7,089 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,227 60
2024 General $1,199 64
2023 General $1,109 65
2022 General $1,074 58
2021 General $1,156 60
2020 General $799 54
2019 General $525 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Kutikoff
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Karen Kutikoff were reported at $1,227. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Karen Kutikoff Internal Medicine median Middle half National median
2019 $525 $159 $48–$570 $163
2020 $799 $119 $33–$402 $114
2021 $1,156 $135 $37–$521 $132
2022 $1,074 $141 $42–$496 $149
2023 $1,109 $149 $45–$519 $160
2024 $1,199 $154 $47–$537 $164
2025 $1,227 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,358 69 payments
  2. Lilly USA, LLC $830 48 payments
  3. AstraZeneca Pharmaceuticals LP $699 40 payments
  4. Pfizer Inc. $684 33 payments
  5. Novo Nordisk Inc $638 40 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $457 26 payments
  7. GlaxoSmithKline, LLC. $439 22 payments
  8. Allergan Inc. $163 13 payments
  9. Idorsia Pharmaceuticals US Inc $157 8 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $146 8 payments
  11. Other $1,519 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,089 393 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $957 50 payments
  2. QULIPTA $579 30 payments
  3. Ozempic $565 35 payments
  4. NURTEC ODT $512 26 payments
  5. ZAVZPRET $512 26 payments
  6. XIFAXAN $495 28 payments
  7. RYBELSUS $479 30 payments
  8. FARXIGA $451 28 payments
  9. TRELEGY ELLIPTA $416 21 payments
  10. MOUNJARO $373 23 payments
  11. Other $4,035 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

4,539

Median for Internal Medicine: 777

Drug cost

$344,667

Median for Internal Medicine: $73,373

Branded share of claims

20%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 86 $102,732
Ozempic Semaglutide Brand 48 $42,979
Trulicity Dulaglutide Brand 23 $39,064
Jardiance Empagliflozin Brand 11 $18,491
Xarelto Rivaroxaban Brand 22 $16,751
Eliquis Apixaban Brand 17 $16,297
Farxiga Dapagliflozin Propanediol Brand 12 $16,111
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 25 $15,194
Myrbetriq Mirabegron Brand 12 $8,740
Synthroid Levothyroxine Sodium Brand 78 $6,997

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$105,081

Medicare's payments for the services billed

Medicare patients

277

Average age 74

Services billed

1,818

200 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Ischemic heart disease 26%
Diabetes 24%
Chronic kidney disease 21%
Osteoporosis 20%
Depression 19%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $145
$145 — —
UBRELVY
  • AbbVie, Inc. $113
$113 — —
NURTEC ODT
  • PFIZER INC. $90
$90 — —
ZAVZPRET
  • PFIZER INC. $90
$90 — —
MOUNJARO
  • Lilly USA, LLC $81
$81 86 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record